Circ_0001947 encapsulated by small extracellular vesicles promotes gastric cancer progression and anti-PD-1 resistance by modulating CD8+ T cell exhaustion-Reference-Cited by-同舟云学术

Circ_0001947 encapsulated by small extracellular vesicles promotes gastric cancer progression and anti-PD-1 resistance by modulating CD8+ T cell exhaustion

Published:2024-09-14 Issue:1 Volume:22 Page:
ISSN:1477-3155
Container-title:Journal of Nanobiotechnology
language:en
Short-container-title:J Nanobiotechnol

Author:

Wang Bingyu,Liu Wenbo,Zhang Mingming,Li Yong,Tang Hongyue,Wang Yingying,Song Chao,Song Buyun,Tan Bibo^ORCID

Funder

Hebei Provincial Department of Science and Technology

Health Commission of Hebei Province

Hebei Medical University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12951-024-02826-5.pdf

Reference45 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414–27. e13.

3. Janjigian YY, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30.

4. Hogner A, Moehler M. Immunotherapy in Gastric Cancer. Curr Oncol. 2022;29(3):1559–74.

5. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy alone for patients with First-line, Advanced Gastric Cancer: the KEYNOTE-062 phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571–80.